Drug Trial Radar · NCT06441682
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
60
Actual
Start
Oct 23, 2024
Primary completion
Aug 12, 2026
Study completion Aug 12, 2026
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Jun 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period when all participants will receive the same dose of ARGX-119. Participation in the study will last up to approximately 100 weeks.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ARGX-119Biological
Intravenous infusion of ARGX-119
PlaceboOther
Intravenous infusion of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assessment of adverse events (AEs)Time frame: Up to week 96
Locations
9 sites in 6 countries. Site status is shown where the registry gives one.
UZ Leuven
Leuven, Belgium
Kaye Edmonton Clinic
Edmonton, Canada
Montreal Neurological Institute and Hospital
Montreal, Canada
Aarhus Universitets Hospital
Aarhus, Denmark
Bispebjerg University Hospital
Copenhagen, Denmark
Hôpital La Pitié Salpêtrière
Paris, France
CHU Bretonneau
Tours, France
UMC Utrecht
Utrecht, Netherlands
Akademiskt specialistcentrum Karolinska Institutet
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.